Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 11.7% during the third quarter, Holdings Channel reports. The institutional investor owned 5,143,330 shares of the medical research company’s stock after buying an additional 538,545 shares during the period. Amgen makes up 0.8% of Janus Henderson Group PLC’s portfolio, making the stock its 15th biggest holding. Janus Henderson Group PLC’s holdings in Amgen were worth $1,657,183,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of AMGN. Capital Performance Advisors LLP bought a new stake in shares of Amgen in the third quarter valued at approximately $25,000. Hershey Financial Advisers LLC purchased a new stake in Amgen during the 2nd quarter worth about $30,000. nVerses Capital LLC purchased a new position in shares of Amgen in the second quarter worth $31,000. Bbjs Financial Advisors LLC purchased a new position in shares of Amgen in the 2nd quarter valued at approximately $33,000. Finally, Matrix Trust Co bought a new position in Amgen in the 3rd quarter worth $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on AMGN shares. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 28th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Wolfe Research assumed coverage on Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $323.05.

Amgen Stock Performance

AMGN opened at $278.10 on Tuesday. Amgen Inc. has a 52-week low of $257.80 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market cap of $149.49 billion, a PE ratio of 35.61, a price-to-earnings-growth ratio of 3.13 and a beta of 0.55. The stock has a 50-day moving average of $311.37 and a 200-day moving average of $317.16.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period last year, the business posted $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, equities research analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.24%. Amgen’s dividend payout ratio (DPR) is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.